Microsponges: A novel strategy for drug delivery system

Santanu Kaity, Sabyasachi Maiti, Ashoke Kumar Ghosh\(^1\), Dilipkumar Pal\(^1\), Animesh Ghosh\(^2\), Subhram Banerjee\(^1\)

Department of Pharmaceutics, Gupta College of Technological Sciences, Ashram More, G.T. Road, Asansol-713 301, West Bengal,\(^1\) College of Pharmacy, Institute of Foreign Trade and Management, Lodhipur Rajput, Delhi Road, Moradabad - 244 001, Uttar Pradesh,\(^2\) Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi - 835 215, Jharkhand, India

DOI: 10.4103/0110-5558.72416

J. Adv. Pharm. Tech. Res.

Abstract

Microsponges are polymeric delivery systems composed of porous microspheres. They are tiny sponge-like spherical particles with a large porous surface. Moreover, they may enhance stability, reduce side effects and modify drug release favorably. Microsponge technology has many favorable characteristics, which make it a versatile drug delivery vehicle. Microsponge Systems are based on microscopic, polymer-based microspheres that can suspend or entrap a wide variety of substances, and can then be incorporated into a formulated product such as a gel, cream, liquid or powder. The outer surface is typically porous, allowing a sustained flow of substances out of the sphere. Microsponges are porous, polymeric microspheres that are used mostly for topical use and have recently been used for oral administration. Microsponges are designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and also to enhance stability, reduce side effects, and modify drug release.

Key words: Controlled release, drug delivery, healthcare systems, microsponges

INTRODUCTION

In recent years, there has been considerable emphasis given to the development of novel microsponge base drug delivery systems, in order to modify and control the release behavior of the drugs. By incorporation into a carrier system, it is possible to alter the therapeutic index and duration of the activity of drugs. The ever-increasing interest among consumers with regard to skin care and skin treatment products has been fostered by the widespread use of ingredients like α-hydroxy acids and vitamins in topical products, which can induce perceivable and demonstrable benefits — especially in aging or photodamaged skin. Although quite useful, in many instances, these ingredients may produce irritancy; such irritancy can be perceived as burning, stinging or redness and particularly occurs in individuals with sensitive skin. Recognizing this problem, the formulators have attempted to deal with this problem in one of the two methods. They have reduced the concentration of such ingredients, but in the process, sacrificed efficacy. They have also modified the vehicle in order to make the product more emollient or skin-compatible.\(^1\) However, this approach, in many cases, also reduces the beneficial effects of the final product. The expanding arena of emerging drugs, increased sensitivity to clinical outcomes, and healthcare costs are driving the need for alternative drug delivery methods and devices. Drug delivery systems that can precisely control the release rates or target drugs to a specific body site have had an enormous impact on the healthcare system. Several predictable and reliable systems been developed for systemic drugs under the heading of transdermal delivery systems (TDS) using the skin as a portal of entry.\(^2\) It has improved the efficacy and safety of many drugs that may be better administered through skin. However, TDS is not practical for delivery of materials whose final target is the skin itself. Controlled release of drugs onto the epidermis with an assurance that the drug remains primarily localized and does not enter the systemic circulation in significant amounts, is an area of research that has only recently been addressed with success. No efficient vehicles have been developed for controlled and localized delivery of drugs into the stratum corneum and underlying skin layers and not beyond the epidermis. Moreover, the application of topical drugs has many problems, such as, ointments that are often aesthetically unappealing, greasiness, stickiness, and so on, that often results in lack of patient compliance. These vehicles require a high concentrations of active agents for effective therapy because of their low efficiency of delivery system, resulting in irritation and allergic reactions in significant users. Other drawbacks of topical formulations are uncontrolled evaporation of the active ingredient, unpleasant odor, and the potential incompatibility of the drugs with the vehicles. Conventional formulations of topical drugs are intended to work on the outer layers of the skin. Typically, such products release their active ingredients upon application, producing a highly concentrated layer of active ingredient...
that is rapidly absorbed. Thus the need exists for a system
to maximize the amount of time that an active ingredient is
present either on the skin surface or within the epidermis,
while minimizing its transdermal penetration into the body.
Microsponges are microscopic spheres capable of absorbing
skin secretions, therefore reducing oiliness and shine from
the skin. Spherical particles composed of clusters of even
tinier spheres are capable of holding four times their weight
in skin secretions. Microsponge particles are extremely
small, inert, indestructible spheres that do not pass through
the skin. Rather, they collect in the tiny nooks and crannies
of the skin and slowly release the entrapped drug, as
the skin needs it. The microspponge system can prevent
excessive accumulation of ingredients within the epidermis
and the dermis. Potentially, the microspponge system can
significantly reduce the irritation of effective drugs without
reducing their efficacy. The empty spheres are then washed
away with the next cleansing. The microspponge delivery
system fulfills these requirements and has resulted in a new
generation of very well-tolerated and highly efficacious,
novel products. These products are typically presented to
the consumer in conventional forms like creams, gels or
lotions and they contain a relatively high concentration of
active ingredients.

Microsponges are patented polymeric delivery systems
consisting of porous microspheres that can entrap a wide
range of active ingredients such as emollients, fragrances,
esential oils, sunscreens, and anti-infective, anti-fungal,
and anti-inflammatory agents. Like a true sponge, each
microsphere consists of a myriad of interconnecting voids
within a non-collapsible structure, with a large porous
surface. The microspponge technology was developed by
Won in 1987, and the original patents were assigned to
Advanced Polymer Systems, Inc. This company developed
a large number of variations of the technique and applied
those to the cosmetic as well as over-the-counter (OTC) and
prescription pharmaceutical products. At the present time,
this interesting technology has been licensed to Cardinal
Health, Inc., for use in topical products. The size of the
microsponges can be varied, usually from 5 – 300 µm in
diameter, depending upon the degree of smoothness or
after-feel required for the end formula. Although the
microspponge size may vary, a typical 25 µm sphere can
have up to 250000 pores and an internal pore structure
equivalent to 10 ft in length, providing a total pore volume
of about 1 ml/g. This results in a large reservoir within each
microspponge, which can be loaded with up to its own weight
of active agent. The microspponge particles themselves
are too large to be absorbed into the skin and this adds a
measure of safety to these microspponge materials. Another
safety concern is the potential bacterial contamination of the
materials entrapped in the microspponge. As the size of the
pore diameter is smaller, the bacteria ranging from 0.007
to 0.2 µm cannot penetrate into the tunnel structure of the
microsponges [Figure 1].

Potential Advantages of the Microspponge Drug
Delivery System

- Microcapsules cannot usually control the release rate
  of the active pharmaceutical ingredients (API). Once
  the wall is ruptured the API contained within the
  microcapsules will be released. Can the MDS can do it,
  is the question.
- Liposomes suffer from a lower pay load, difficult
  formulation, limited chemical stability, and microbial
  instability. Do the MDS have a wide range of chemical
  stability and are they easy to formulate?
- MDS have stability over a pH range of 1 – 11.
- Stable up to temperature 130°C.
- Pay load is up to 50 – 60%.
- Free flowing and cost effective.
- Microsponges are microscopic spheres capable of
  absorbing skin secretions, therefore, reducing oiliness
  and shine from the skin.

Properties of the Actives for the Entrapment into
Microsponges

- It should be either fully miscible in a monomer or
capable of being made miscible by the addition of a
small amount of a water-immiscible solvent.
- It should be water immiscible or at most only slightly
soluble.
- It should be inert to monomers and should not increase
the viscosity of the mixture during formulation.
- It should be stable when in contact with the
polymerization catalyst and under conditions of
polymerization.
- The spherical structure of the microsponges should not
collapse.

Methods of Preparation of Microsponges

Liquid–liquid suspension polymerization

In general, a solution is made comprising of monomers and
the functional or active ingredients, which are immiscible
with water. This phase is then suspended with agitation
in an aqueous phase, usually containing additives, such
as surfactants and dispersants, to promote suspension.
Once the suspension is established with discrete droplets
of the desired size, polymerization is effected by activating
the monomers either by catalysis, increased temperature
or irradiation. As the polymerization process continues,
a spherical structure is produced containing thousands
of microsponges bunched together like grapes, forming

---

Figure 1: Schematic representation of the distribution of the loaded
material (active) on skin
interconnecting reservoirs [Figure 2].

Once the polymerization is complete the solid particles that result from the process are recovered from the suspension. The particles are then washed and processed until they are substantially ready for use. The microspponge products can be made using styrene and divinylbenzene or methyl methacrylate and ethylene glycol dimethacrylate as starting materials.\[5\]

**Quasi-emulsion solvent diffusion**

To prepare the inner organic phase, Eudragit RS 100 is dissolved in ethyl alcohol. Next, the drug is added to the solution and dissolved under ultrasonication at 35°C. The inner phase is poured into the polyvinyl alcohol solution in water (outer phase). Following 60 minutes of stirring, the mixture is filtered, to separate the microsponges. The microsponges are dried in an air-heated oven at 40°C for 12 hours [Figure 3].\[6\]

Ingredients can be entrapped in microsponge polymers either at the time of synthesis, or if too labile to withstand polymerization conditions, they can be post-loaded after the microsphere structure has been pre-formed. In general, the latter process is the preferred mode, as many cosmetic ingredients, and most pharmaceutical ones, would decompose at the temperatures employed for polymerization.

**Hypothetical mechanism of action**

The active ingredient is added to the vehicle in an entrapped form. As the microspponge particles have an open structure (i.e., they do not have a continuous membrane surrounding them), the active is free to move in and out from the particles and into the vehicle until equilibrium is reached, when the vehicle becomes saturated. Once the finished product is applied to the skin, the active that is already in the vehicle will be absorbed into the skin, depleting the vehicle, which will become unsaturated, therefore, disturbing the equilibrium. This will start a flow of the active from the microspponge particle into the vehicle, and from it to the skin, until the vehicle is either dried or absorbed. Even after that the microspponge particles retained on the surface of the stratum corneum will continue to gradually release the active to the skin, providing prolonged release over time. This proposed mechanism of action highlights the importance of formulating vehicles for use with microspponge entrapments. If the active is too soluble in the desired vehicle during compounding of the finished products, the products will not provide the desired benefits of gradual release. Instead they will behave as if the active was added to the vehicle in a free form. Therefore, while formulating microspponge entrapments, it is important to design a vehicle that has minimal solubilizing power for the actives. This principle is contrary to the conventional formulation principles usually applied to topical products. For these conventional systems it is normally recommended to maximize the solubility of the active in the vehicle. When using microspponge entrapments, some solubility of the active in the vehicle is acceptable, because the vehicle can provide the initial loading dose of the active until release from the microspponge is activated by the shift in equilibrium from the polymer into the carrier. Another way to avoid undesirable premature leaching of the active from the microspponge polymer is to formulate the product with some free and some entrapped active, so the vehicle is pre-saturated. In this case there will not be any leaching of the active from the polymer during compounding. The rate of active release will ultimately depend not only on the partition coefficient of the active ingredient between the polymer and the vehicle (or the skin), but also on some of the parameters that characterize the beads. Examples of these include surface area and primarily, mean pore diameter.\[7\] Release can also be controlled through diffusion or other triggers such as

---

**Figure 2:** Reaction vessel for microspponge preparation by liquid–liquid suspension polymerization

**Figure 3:** Preparation of microsponges by the quasi-emulsion solvent diffusion method
moisture, pH, friction or temperature.

**Characterization of the microsponge**

The microsponges are generally characterized for particle size, shape, pore volume, pore diameter. And so on. Different parameters and evaluation methods for microsponges is given in Table 1.

**Microsponge-based Delivery Systems for Drug Triggering**

**Topical drug delivery using microsponge technology**

Microsponic delivery of Benzoyl peroxide was developed using an emulsion solvent diffusion method, by adding an organic internal phase containing benzoyl peroxide, ethyl cellulose, and dichloromethane into a stirred aqueous phase containing polyvinyl alcohol, and by suspension polymerization of styrene and divinyl benzene. The prepared microsponges were dispersed in a gel base and the microspongic gels were evaluated for anti-bacterial and skin irritancy. The entrapped system released the drug at a slower rate than the system containing free BPO. The topical delivery system with reduced irritancy was successfully developed. A new formulation of Hydroquinone (HQ) 4%, with retinol 0.15%, entrapped in microsponge reservoirs, was developed to release HQ gradually, to prolong exposure to treatment and to minimize skin irritation. The safety and efficacy of this product were evaluated in a 12-week, open-label study. In this open-label study, HQ 4% with retinol 0.15% was safe as well as effective. The microspongic system for topical delivery of fluconazole gel was observed to have the potential to extend the release. An MDS system for retinoic acid was developed and tested for drug release and anti-acne efficacy. Statistically significant, greater reductions in inflammatory and non-inflammatory lesions were obtained with tretinoin entrapped in the microsponge. Topical analgesic, anti-inflammatory, and counter-irritant drugs in a microsponge® are used for the management of the musculoskeletal system.

**Oral drug delivery using microsponge technology**

In oral applications, the microsponge system has been shown to increase the rate of solubilization of poorly water-soluble drugs by entrapping such drugs in the microsponge system’s pores. As these pores are very small, the drug is in effect reduced to microscopic particles and the significant increase in the surface area thus greatly increases the rate

| Table 1: Different parameters and characterization methods for microsponges |
|------------------------|--------------------------|-----------------|
| Parameters | Characterization methods | References |
| Measurement of particle size, size distribution, and polydispersity index | Laser light diffractometry | [8] |
| Morphology and surface topography | Scanning electron microscopy | [9] |
| Determination of true density | Ultra-pycnometer under helium gas (Displacement method) | [10] |
| Characterization of pore structure, Total pore volume, Material volume, Material density, Interstitial void volume, Percent porosity, Percent porosity filled, Pore volume distribution by pore size, Pore area, number of pores Pore cavity to pore throat size ratio, Pore cavity sizes, Pore throat size, Pore fractal dimensions, Pore tortuosity and tortuosity factor | Mercury intrusion porosimetry | [10-12] |
| Drug polymer interaction studies | Fourier transform infra-red spectroscopy (FTIR) study | [13] |
| Study of glass-transition temperature | Differential scanning calorimetry | [13] |
| Effect of polymerization on crystallinity of the drug | X-ray diffraction (XRD) studies | [14] |
| Compatibility studies | Thin layer chromatography (TLC) | [15] |
| Polymer / Monomer composition | By plotting cumulative percent drug release against time | [16-17] |
| Resiliency (viscoelastic properties) | By considering release as a function of cross-linking with time | [18] |
| Release mechanisms | By proper manipulation of the aforementioned programmable parameters | [19] |
| Safety considerations | Skin irritation studies in rabbits; eye irritation studies in rabbits; oral toxicity studies in rats; mutagenicity in bacteria, and allergenicity in guinea pigs | [20-21] |
| Drug release from the topical semi-solid formulation | Franz-type static diffusion cells | [22] |
of solubilization. Controlled oral delivery of ibuprofen microsponges is achieved with an acrylic polymer, eudragit RS, by changing their intraparticle density.[31] Sustained release formulation of chlorpheniramine maleate, using powder-coated microsponges, is prepared by the dry impact blending method, for oral drug delivery.[32] Controlled oral delivery of Ketoprofen prepared by quasi-emulsion solvent diffusion method with Eudragit RS 100 and afterwards tablets of microsponges were prepared by the direct compression method. Results indicated that compressibility was much improved in the physical mixture of the drug and polymer; due to the plastic deformation of the sponge-like microsponge structure, producing mechanically strong tablets.[33] Colon-specific, controlled delivery of flurbiprofen, was conducted by using a commercial Microsponge® 5640 system. In vitro studies exhibited that compression-coated colon-specific tablet formulations started to release the drug at the eighth hour, corresponding to the proximal colon arrival time, due to addition of the enzyme, following a modified release pattern, while the drug release from the colon-specific formulations prepared by pore plugging the microsponges showed an increase at the eighth hour, which was the point of time when the enzyme addition was made.[33]

Microsponge-based Delivery Systems for Bone and Tissue Engineering

Bone-substitute compounds were obtained by mixing pre-polymerized powders of polymethylmethacrylate and liquid methylmethacrylate monomer with two aqueous dispersions of a-tricalcium phosphate grains and calcium-deficient hydroxyapatite powders. The final composites appeared to be porous and acted as microsponges.[34] The basic fibroblast growth factor (bFGF) incorporated in a collagen sponge sheet was sustained released in the mouse sub-cutis according to the biodegradation of the sponge matrix, and exhibited local angiogenic activity in a dose-dependent manner. Intra-muscular injection of collagen microsponges incorporating bFGF, induced a significant increase in the blood flow, in the murine ischemic hind limb, which could never have been attained by the bolus injection of bFGF. These results suggest the significance and therapeutic utility of the type I collagen as a reservoir of bFGF.[35] A biodegradable graft material containing the collagen microsponge was developed for cardiovascular tissue grafting, as it would permit the regeneration of the autologous vessel tissue.[36] A thin biodegradable hybrid mesh of synthetic poly (DL-lactic-co-glycolic acid) (PLGA) and naturally derived collagen was used for a three-dimensional culture of human skin fibroblasts. The hybrid mesh was constructed by forming web-like collagen microsponges in the openings of a PLGA-knitted mesh.[37] A tissue-engineered patch made of our biodegradable polymer and collagen-microsponge provided good in situ regeneration at both the venous and arterial wall, suggesting that this patch could be used as a novel surgical material for the repair of the cardiovascular system.[38]

Potential applications of microsponge systems

Microsponges are used widely to develop drug and cosmetic products for topical administration and recently for oral administration [Table 2]. These are designed to deliver the drug efficiently at the minimum dose and also to enhance stability, reduce side effects, and modify drug release.[40]

Marketed formulation based on microsponge materials

List of marketed products using microsponge drug delivery system are given in Table 3.

Future prospects

Microsponges are one of the novel drug delivery systems, which were originally developed for topical delivery of drugs. They can also be used for tissue engineering and controlled oral delivery of drugs using biodegradable polymers. It provides a wide range of formulating advantages. Liquids can be transformed into free flowing powders. Formulations can be developed with otherwise incompatible ingredients, with prolonged stability, without the use of preservatives. Therefore, microsponges will be an ideal drug delivery system related to formulations like the transdermal delivery system. As it requires vehicles at a higher concentration in order to dissolve the API for effective therapy, it causes irritation and hypersensitivity reactions in significant users. Another demerit of topical formulations is uncontrolled evaporation of the cative ingredient, unpleasant odor, and the potential incompatibility of drugs with the vehicles. Conventional formulations of topical drugs are intended to work on the outer layers of the skin. Typically, such products release their active ingredients upon application, producing a highly concentrated layer of an active ingredient that is rapidly absorbed. Thus, the need exists for a system to maximize the amount of time that an active ingredient is present either on the skin surface or within the epidermis. Some microsponge-based products are already approved; several others are currently under development and clinical assessment.

CONCLUSION

The microsponge delivery system is a unique technology for the controlled release of macroporous beads, loaded with active agent, offering a potential reduction in side effects, while maintaining their therapeutic efficacy. The microsponge drug delivery system offers entrapment of its ingredients and is believed to contribute toward reduced side effects, improved stability, increased elegance, and enhanced formulation flexibility. In addition, numerous studies have confirmed that microsponge systems are non-irritating, non-mutagenic, non-allergenic, and non-toxic. This technology is being used currently in cosmetics,
Table 2: Therapeutic applications of microsponges

| Product name                          | Advantages                                                                                                                                  | Manufacturer                          |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Retin-A-Micro                         | 0.1 and 0.04% tretinoin entrapped in MDS, for topical treatment of acne vulgaris. This formulation uses patented methyl methacrylate / glycol dimethacrylate cross-polymer porous microspheres to enable inclusion of the active ingredient, tretinoin, in an aqueous gel. | Ortho-McNeil Pharmaceutical, Inc.      |
| Carac cream, 0.5%                     | Carac cream contains 0.5% fluorouracil, with 0.35% being incorporated into a patented porous microsphere (Microsphere) composed of methyl methacrylate / glycol dimethacrylate cross-polymer and dimethicone. Carac is a once-a-day topical prescription product for the treatment of actinic keratoses, a common pre-cancerous skin condition caused by over-exposure to the sun. The product has a number of advantages over the existing topical therapies, including less irritation with shorter duration of therapy and reduced dosage frequency. | Dermik Laboratories, Inc. Berwyn, PA 19312 USA |
| Line eliminator dual retinol facial treatment | Lightweight cream with a retinol (pure Vitamin A) in MDS, delivers both immediate and time-released wrinkle-fighting action. | Avon                                   |
| Retinol cream                         | The retinol molecule is kept in the microsphere system to protect the potency of vitamin A. This helps to maximize the retinol dosage, while reducing the possibility of irritation. Retinol is a topical vitamin A derivative, which helps maintain healthy skin, hair, and mucous membranes. | Biomedic                               |
| Retinol 15 nightcream                 | A nighttime treatment cream with Microsphere technology using a stabilized formula of pure retinol and Vitamin A. Continued use of Retinol 15 will result in the visible diminishment of fine lines and wrinkles, a noticeable improvement in skin discolorations due to aging, and enhanced skin smoothness. | Sothys                                 |
| EpiQuin micro                         | The Microsphere® system uses microscopic reservoirs that entrap hydroquinone and retinol. The microspheres release these ingredients into the skin gradually throughout the day. This provides the skin with continuous exposure to hydroquinone and retinol over time, which may minimize skin irritation. | Skin Medica Inc                        |
| Sports cream RS and XS               | Topical analgesic-anti-inflammatory and counterirritant actives in a Microsphere® Delivery System (MDS) for the management of musculoskeletal conditions. | Embil Pharmaceutical Co. Ltd.          |
| Salicylic peel 20                    | Deep BHA peeling agent for (professional use only): Salicylic acid 20%, Microsphere Technology, Excellent exfoliation and stimulation of the skin for more resistant skin types or for faster results. Will dramatically improve fine lines, pigmentation, and acne concerns. | Biophora                               |
| Salicylic peel 30                    | Deeper BHA peeling agent for (professional use only): Salicylic acid 30%, Microsphere Technology, Most powerful exfoliation and stimulation of the skin. For more resistant skin types or for faster results. Will dramatically improve fine lines, pigmentation, and acne concerns. | Biophora                               |
| Micro peel plus                      | The MicroPeel® Plus procedure stimulates cell turnover through the application of salicylic acid in the form of microcrystals using Microsphere® technology. These microcrystals target the exact areas on the skin that need improvement. The MicroPeel® Plus aggressively outperforms other superficial chemical peels by freeing the skin of all dead cells, while doing no damage to the skin. | Biomedic                                |
| Oil free matte block spf-20          | This invisible sunscreen provides a shield for the skin from damaging UV rays and controls oil production. Microsphere technology absorbs the oil, maintaining an all-day matte finish and preventing shine without any powdery residue. Oil-free formula contains soothing Green Tea to help calm inflammation caused by breakouts. Contains no artificial fragrance or color. Cornstarch and Vinyl Dimethicone / Methicone Silsesquioxane Cross-polymer act as microsponges to absorb excess surface oils on skin. | Dermalogica                            |
| Oil control lotion                   | A feature-light lotion with technically advanced microsponges that absorb oil on the skin's surface during the day, for a matte finish. Eliminate shine for hours with this feature-weight lotion, formulated with oil-absorbing Microsphere® technology and hydrating botanicals. The natural-antibiotic Skin Response Complex soothes inflammation and tightness to promote healing. Acne-Prone, oily skin conditions. | Fountain Cosmetics                      |
| Lactrex™ 12% moisturizing cream      | Lactrex™ 12% Moisturizing cream contains 12% lactic acid as the neutral ammonium salt and ammonium lactate. Microsphere® technology has been included for comfortable application and long-lasting moisturization. Lactrex™ also contains water and glycerin, a natural humectant, to soften and help moisturize dry, flaky, cracked skin. | SDR Pharmaceuticals, Inc., Andover, NJ, U.S.A. 07821 |

Contd...
over-the-counter skin care, sunscreens, and prescription products. This kind of drug delivery technology may lead to a better understanding of the healing of several diseases. Hence, the microsponge-based drug delivery technology is likely to become a valuable drug delivery matrix substance for various therapeutic applications in the future.

REFERENCES

1. Saxena S, Nacht S. Polymeric porous delivery systems: Polytrap and Microponge. In: Delivery System Handbook for Personal Care and Cosmetic Products: Technology, Applications and Formulations. New York: William Andrew Publishing; 2005. p. 333-51.
2. Kydonieus AF, Berner B. Transdermal Delivery of Drugs. Boca Raton: CRC Press; 1987.
3. Nacht S, Kantz M. The microponge: A novel topical programmable delivery system. Top Drug Deliv Syst 1992;42:299-325.
4. Won R. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen. Patent No. 4690825. US: 1987.
5. Hainey P, Huxham IM, Rowatt B, Sherrington DC. Synthesis and ultrastructural studies, of styrene-divinylbenzene polyhexe polymers. Macromolecules 1991;24:117-21.
6. Orlu M, Cevher E, Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponge. Int J Pharm 2006; 318:103-17.
7. Embil K, Nacht S. The Microponge® delivery system (MDS): A topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 1996;13:575-88.
8. Martin A, Swarbrick J, Cammarrata A. Physical Pharmacy-Physical Chemical Principles in Pharmaceutical Sciences. 3rd ed. Philadelphia: Lea and Febiger;1991. p. 527.
9. Emanuele AD, Dinarvand R. Preparation, Characterization and Drug Release from Thermo responsive Microspheres. Int J Pharmaceutics 1995;118:237-42.
10. D souza JI. The Microponge Drug Delivery System: For Delivering an Active Ingredient by Controlled Time Release. Pharmainfo net 2008;6:3.
11. Washburn EW. Note on a method of determining the distribution of pore sizes in a porous material. Proc Natl Acad Sci U.S.A. 1921;7:115-6.
12. Orr Jr C. Application of mercury penetration to material analysis. Powder Technol 1969;3:117-23.
13. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyama S. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci 1991;80:472-8.
14. Bodmeier R, Chen H. Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen. J Control Release 1989;10:167-75.
15. Jones DS, Pearce KJ. Investigation of the effects of some process variables on, microencapsulation of propranolol HCl by solvent evaporation method. Int J Pharm 1995;118:99-205.
16. Junik,Nakano M. Preparation and evaluation invitro of polylacticacid microspheres containing local anesthetic. Chem Pharm Bull 1981;29:3363-8.
17. Barkai A, Pathak V, Benita S. Polycarlylate (Uedragit retard) microspheres for oral controlled release of nifedipine. L Formulation design and process optimization. Drug Dev Ind Pharm 1990;16:2057-75.
18. Comoglu T, Gunul N, Baykara T. Preparation and invitro evaluation of modified release ketoprofen microsponge. Farmaco 2003;58:101-6.
19. Shah VP. Determination of invitro Release from Hydrocortisone Creams. Int J Pharm 1989;53:53-9.
20. Sato T, Kanke M, Schroeder G, Deluca P. Porous biodegradable microspheres for controlled drug delivery. I: Assessment of processing conditions and solvent removal techniques. Pharm Res 1998;5:21-30.

21. Draize JH, Woodard J, Calvary HO. Methods for the Study of Irritation and Toxicity of Substances Applied Topically to the Skin and Mucous Membranes. J Pharmacol and Exp Ther 1944;82:377-89.

22. Franz TJ. Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol 1975;45:498-503.

23. Yazici E, Kas HS, Hincal AA. Microsponges, Farmasotik Bilimler Dergisi (Turkey). 1994;19:121-8.

24. Wester R, Patel R, Natch S, Leyden J, Maibach H. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Derm 1991;24:720-6.

25. D'souza JJ, Sabooji JK, Kiledar SG, More NH. Design and Evaluation of Benzoyl Peroxide Microsponges to Enhance Therapeutic Efficacy in Acne Treatment. 20th FAPA Congress, Bangkok, Thailand: FAPA Congress; Nov 30 - Dec 3, 2004.

26. D'souza JI. In-vitro Antibacterial and Skin Irritation Studies of Microsponges of Benzoyl Peroxide. Indian Drugs 2001;38:23.

27. Fincham JE, Karnik KA. Patient Counseling and Derm Therapy. US Pharm 1994;19:56-57, 61-2, 66, 71-2, 74, 77-8, 81-2.

28. D'souza JJ, Masvekar RR, Pattekari PP, More HN. Microspongic Delivery of Fluconazole For Topical Application, 1st Indo-Japanese International Conference On Advances In Pharmaceutical Research And Technology. Mumbai, India: Pharmaceutical Research And Technology; 2005. p. 25-9.

29. Grimes PE. A microspunge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and post-inflammatory hyperpigmentation. Cutis 2004;74:362-8.

30. Embil VP. OTC External analgesic cream/topical analgesic-anti-inflammatory, counterirritant utilizing the Microspunge Delivery System (MDS) for controlled release of actives. Patent Application No: 0101058.6. UK: 2000.

31. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Control of Prolonged Drug Release and Compression Properties of Ibuprofen Microsponges with Acrylic Polymer, Eudragit RS, by changing their Intraparticle Density. Chem Pharm Bull 1992;40:196-201.

32. Aritomi H, Yamasaki Y, Yamada K, Honda H, Koshi M. Development of sustained release formulation of chlorpheniramine maleate using powder coated microsponges prepared by dry impact blending method. J Pharm Sci Tech 1996;56:49-56.

33. OrluM, Cevher E, Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int J Pharm 2006;318:103-17.

34. Chen G, Ushida T, Tateishi T. A Biodegradable Hybrid Sponge Nested With Collagen Microsponges. J Biomed Mater Res 2000;51:273-9.

35. Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, et al. Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release 2004;94:281-92.

36. Iwai S, Sawa Y, Ichikawa H, Taketani S, Uchimura E, Chen G, et al. Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis. J Thorac Cardiovasc Surg 2004;128:472-9.

37. Chen G, Sato T, Ohgushi H, Ushida T, Tateishi T, Tanaka J. Culturing of skin fibroblasts in a thin PLGA–collagen hybrid mesh. Biomaterials 2005;26:2559-66.

38. Iwai S, Sawa Y, Taketani S, Torikai K, Hirakawa K, Matsuda H. Novel Tissue-Engineered Biodegradable Material for Reconstruction of Vascular Wall. Ann Thorac Surg 2005;80:1821-7.

39. Grimee PE, Meraz M. A new microentrapped 4% hydroquinone formulation for treatment of hyperpigmentation. 60th Annual meeting of American Academy of Dermatology. La Poeter New Orleane: Feb 22-27, 2002.

40. Khopade AJ, Jain S, Jain NK. The Microsponge. East Pharm 1996;39:49-53.

Source of Support: Nil, Conflict of Interest: Nil.